MELISSA TERRY: Open Payments
NPI 1083255855 · WABASH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,044 in 57 payments from 13 companies in 2025. Trend: 2023 $1,822 · 2024 $779 · 2025 $1,044
Food & beverage: $913Education: $132
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 13 | $263 |
| Vanda Pharmaceuticals Inc. | 14 | $158 |
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Alkermes, Inc. | 3 | $80 |
| Neurocrine BioSciences, Inc. | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $69 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Janssen Pharmaceuticals, Inc | 3 | $62 |
| Lundbeck LLC | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
Products named: REXULTI, FANAPT, COBENFY, ARISTADA, INGREZZA, Qelbree, Jornay PM, SPRAVATO.
Industry payments across IN — which companies pay providers there.
